{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-000929","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.333167+00:00","generated_at":"2026-06-20T18:26:48.292694+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis sells SMA and Pelacarsen royalties to Royalty Pharma for $500M upfront, up to $625M in milestones","bullets":["Sold 25% of Biogen SMA royalties (25% 2023-2027, 45% thereafter) and 25% of Novartis Pelacarsen royalties.","Initial purchase price $500M; additional milestone payments up to $625M, subject to achievement.","SMA royalty capped at $475M or $550M depending on timing of Pelacarsen FDA approval.","Covenants restrict amending/terminating underlying license agreements; extra payments if competing product commercialized."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-000929","json":"https://secwatch.observer/filing/0001140361-23-000929.json","markdown":"https://secwatch.observer/filing/0001140361-23-000929.md","text":"https://secwatch.observer/filing/0001140361-23-000929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123000929/0001140361-23-000929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123000929/brhc10046438_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:26:48.292694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a3eba3397140242e4ad5e657986ef1b8aadb161","claim":"IONIS PHARMACEUTICALS INC entered into Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at $500,000,000 (effective 2023-01-08).","evidence_excerpt":"On January 8, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) and its wholly-owned subsidiary, Akcea Therapeutics, Inc. (the “ Subsidiary ”) entered into a royalty purchase agreement (the “ Purchase Agreement ”) with Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (“ Royalty Pharma ”), pursuant to which the Company and the Subsidiary sold to Royalty Pharma: (i) the Company’s right, title and interest in and to: (A) in respect of net sales by Biogen Idec International Holding Ltd (“ Biogen Idec ”) and Biogen MA (“ Biogen MA ”, and together with Biogen Idec, “ Biogen ”) between January 1, 2023 and December 31, 2027, 25%, and (B) in respect of net sales by Biogen Idec commencing on January 1, 2028, 45% of the royalties payable to the Company on annual worldwide net sales up to $1,500,000,000 pursuant to that certain Development, Option and License Agreement by and between the Company and Biogen Idec dated January 3, 2012, as amended (the “ 2012 Bioge","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123000929/0001140361-23-000929-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Royalty Pharma Investments 2019 ICAV"},{"label":"Value","value":"$500,000,000"},{"label":"Effective","value":"2023-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}